Search results
Showing 1351 to 1400 of 3761 results for treatment
Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management.
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making
Recommendation ID CG168/4 Question Truncal treatment with or without concurrent tributary treatment:- What is the clinical...
NG198/2 Question What is the most effective first-line treatment option for any severity of acne vulgaris for people with polycystic...
Physical treatments for acne vulgaris and acne vulgaris-related scarring: What is the effectiveness of chemical peels for the...
NG145/2 Question What is the clinical and cost effectiveness of treatment (antithyroid drugs or radioactive iodine) for improving...
Vutrisiran for treating hereditary transthyretin-related amyloidosis (TA868)
Evidence-based recommendations on vutrisiran (Amvuttra) for treating hereditary transthyretin-related amyloidosis in adults.
Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab (ES1)
Summary of the evidence on rituximab for minimal change disease and focal segmental glomerulosclerosis to inform local NHS planning and decision-making
Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders
Awaiting development Reference number: GID-TA11907 Expected publication date: TBC
Evidence-based recommendations on autologous chondrocyte implantation in people with symptomatic articular cartilage defects of the knee.
In development Reference number: GID-TA11385 Expected publication date: 25 February 2026
Recommendation ID CG123/6 Question Priority of treatment for people with anxiety and depression:- For people with both anxiety and...
Digitally enabled therapies for adults with depression: early value assessment (HTG675)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression.
Antimicrobial prescribing: imipenem with cilastatin and relebactam (ES30)
Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam
Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.
management of Lyme disease:- What are the most clinically and cost-effective treatment options for different clinical presentations of...
Evidence-based recommendations on Synergo for non-muscle-invasive bladder cancer.
This quality standard covers diagnosing and managing gallstones in adults. It also includes managing complications of gallstones, such as an inflamed or infected gallbladder (cholecystitis), blocked and infected bile ducts (cholangitis), and an inflamed pancreas (pancreatitis). It describes high-quality care in priority areas for improvement.
View quality statements for QS104Show all sections
Sections for QS104
- Quality statements
- Quality statement 1: Acute cholecystitis
- Quality statement 2: Urgent endoscopic retrograde cholangiopancreatography within 72 hours
- Quality statement 3: Emergency endoscopic retrograde cholangiopancreatography within 24 hours
- Quality statement 4: Advice to prevent symptoms
- About this quality standard
This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).
Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)
Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making
early-onset infection: What is the optimal antibiotic dosage regimen for the treatment of early-onset neonatal infection? Any...
Early value assessment (EVA) guidance on guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood.
Evidence-based recommendations on gammaCore for cluster headache.
Promoting tolerance of enteral feeds in children and young people: domperidone (ESUOM18)
Summary of the evidence on domperidone to promote tolerance of enteral feeds in children and young people..
Antimicrobial prescribing: meropenem with vaborbactam (ES21)
Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making
Summary of the evidence on flunarizine for treating migraine prophylaxis to inform local NHS planning and decision-making
Evidence-based recommendations on using coronary artery stents in adults.
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)
Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making
This guideline covers the identification, assessment and treatment of attachment difficulties in children and young people up to age 18 who are adopted from care, in special guardianship, looked after by local authorities in foster homes (including kinship foster care), residential settings and other accommodation, or on the edge of care. It aims to address the many emotional and psychological needs of children and young people in these situations, including those resulting from maltreatment.
Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)
Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making
Implanting a baroreceptor stimulation device for resistant hypertension
In development Reference number: GID-IP1180 Expected publication date: TBC
Evidence-based recommendations on dual-chamber pacemakers for treating symptomatic bradycardia caused by sick sinus syndrome without atrioventricular block.
ID NG35/1 Question Diagnostic investigations to predict treatment outcomes:- What is the prognostic value of the Hevylite assay and ratio
This indicator covers the percentage of adults receiving drug treatment for epilepsy who had a structured review in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM209
The NICE glossary provides brief definitions and explanations of terms used on the website. The terms describe how NICE works and how its guidance is produced.
Question What is the effectivness of stains and/or other lipid-lowering treatment in people with type 1 diabetes? Any explanatory...
Frequency of application of topical corticosteroids for atopic eczema (TA81)
Evidence-based recommendations on using topical corticosteroids for people with atopic eczema.
Workplace health: long-term sickness absence and capability to work (QS202)
This quality standard covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence. It covers everyone aged over 16 in full-time or part-time employment (paid or unpaid). It describes high-quality care in priority areas for improvement.
View quality statements for QS202Show all sections
Sections for QS202
suspected late-onset neonatal infection: What is the optimal antibiotic treatment regimen for suspected late-onset neonatal infection?...
NICE is unable to make a recommendation on sacituzumab govitecan (Trodelvy) for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1089
in people with a comorbidity:- What is the impact of comorbidities on treatment outcomes for eating disorders, and whatapproaches are...
Opioid dependence: buprenorphine prolonged-release injection (Buvidal) (ES19)
Summary of the evidence on buprenorphine prolonged-release subcutaneous injection (Buvidal) for opioid dependence to inform local NHS
Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (HTG521)
Evidence-based recommendations on enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors in rheumatoid arthritis. The tests are Promonitor, IDKmonitor, LISA-tracker, RIDASCREEN, MabTrack, and those used by Sanquin Diagnostic Services.
Optimal interventional and conservative treatments at different stages of disease:- What is the optimal treatment...
This quality standard covers interventions to improve the uptake of HIV testing among people who may have undiagnosed HIV. It focuses on increasing testing to reduce undiagnosed infection in people at increased risk of exposure. It describes high-quality care in priority areas for improvement.
View quality statements for QS157Show all sections
Sections for QS157
- Quality statements
- Quality statement 1: Hospitals in areas of high and extremely high HIV prevalence
- Quality statement 2: General practice in areas of high and extremely high HIV prevalence
- Quality statement 3: HIV indicator conditions
- Quality statement 4: Regular HIV testing
- Quality statement 5: People who may have been exposed to HIV
- Update information
- About this quality standard
Recommendation ID NG161/1 Question Risk of systemic anticancer treatment in people with cancer and COVID-19: Are patients with cancer...
This quality standard covers adults with rehabilitation needs as a result of critical illness that required level 2 or level 3 critical care. It describes high-quality care in priority areas for improvement.
View quality statements for QS158Show all sections
Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)
Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children.
Odevixibat for treating progressive familial intrahepatic cholestasis (HST17)
Evidence-based recommendations on odevixibat (Bylvay) for treating progressive familial intrahepatic cholestasis in people 6 months and older.